摘要
目的探讨血清hs-CRP水平与特发性面神经麻痹病情、预后的相关性。方法选取2020年1月-2021年2月在我院神经内科就诊,确诊特发性面神经麻痹患者80例纳入观察组,选取同期来院体检的健康人群80例纳入对照组。观察组患者按照H-B面神经功能分级法分病情轻中度组、重度组;将连续治疗2周后H-B分级Ⅰ级者纳入预后好组,将Ⅱ~Ⅵ级者纳入预后差组,分别记录病情轻中度组、重度组、预后好组、预后差组血清hs-CRP水平。结果观察组血清hs-CRP水平明显高于对照组;观察组中病情重度组治疗前后血清hs-CRP水平明显高于病情轻中度组,预后差组血清hs-CRP水平明显高于预后好组,差异具有统计学意义(P<0.05)。血清hs-CRP水平与病情轻中度、预后好呈负相关,与病情重度、预后差呈正相关。结论hs-CRP是特发性面神经麻痹患者早期判断病情、预后的有效指标。
Objective To investigate the correlation between serum hs-CRP level and the condition and prognosis of idiopathic facial paralysis.Methods From January 2020 to February 2021,80 patients with idiopathic facial paralysis were selected as the observation group,and 80 healthy people were selected as the control group.The patients in the observation group were divided into mild to moderate group and severe group according to the H-B facial nerve function grading method;after two weeks of continuous treatment,the patients with H-B grade I were included in the good prognosis group,and the patients with grade II to VI were included in the poor prognosis group.The serum hs-CRP levels of mild to moderate group,severe group,good prognosis group and poor prognosis group were recorded respectively.Results The serum hs-CRP level of the observation group was significantly higher than that of the control group;the serum hs-CRP level of the observation group before and after treatment was significantly higher than that of the mild to moderate group,the serum hs-CRP level of the poor prognosis group was significantly higher than that of the good prognosis group,the difference was statistically significant(P<0.05).Serum hs-CRP level was negatively correlated with mild to moderate disease and good prognosis,and positively correlated with severe disease and poor prognosis.Conclusion Hs-CRP is an effective index for early diagnosis and prognosis of idiopathic facial paralysis.
作者
何敏
刘志强
蒋玲霞
屈新辉
HE min;LIU Zhiqiang;JIANG Lingxia(Department of Neurology,Second Department of Jiangxi Provincial People's Hospital,Nanchang 330006,Jiangxi Province)
出处
《江西医药》
CAS
2021年第6期731-733,736,共4页
Jiangxi Medical Journal
基金
江西省卫健委科技计划,编号202130068